ACTRN12612000870853尚未招募未知
A phase III randomised study to assess the risk of catheter-associated blood stream infections between the dominant and non-dominant arm in adults with cancer.
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 1,250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 15 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Provision of informed consent
- •2. Inpatients or outpatients with cancer who need to have a CVAD inserted
排除标准
- •1. Contraindication to CVAD insertion on one side of the body. This may include:
- •* patients with breast cancer where there is a preference to insert CVADs in a particular side
- •* prior line related thrombosis where there is a preference to insert CVADs in a particular side
- •* prior difficult line insertion where there is a preference to insert CVADs in a particular side
- •* any other medical reason where the patient’s physician or interventional radiologist believes that insertion on one side is contraindicated
- •2. Implantable ports will not be included in the study
- •3. Peripheral venous catheters are excluded
研究者
相似试验
进行中（未招募）
1 期
SE OF INHALATORY APROTININE AS AN ANTIVIRAL FOR TREATMENT OF SARS-CoV-2 (COVID-19) IN HOSPITALIZED PATIENTS.Patients with moderate SARS-CoV-2 pneumonia confirmed with adiagnosis of polymerase chain reaction (PCR) before randomization. Thepatient should be hospitalized and require ongoing medical care forSARS-CoV-2. With peripheral capillary O2 saturation levels (SpO2 ) >90% breathing ambient air. With radiographic evidence of pulmonaryinfiltrates.EUCTR2020-002434-33-ESHospital General Universitario Ciudad Real105
已完成
不适用
BOOST-NZThe role of oxygen saturation targetting in morbidity and mortality in infants born less than 28 weeks gestationReproductive Health and Childbirth - Childbirth and postnatal careACTRN12605000253606niversity of Otago320
招募中
3 期
A study in blood cancer patients to compare two types of treatment strategy approaches in patients above 15 years of age. Patients will be divided in two equal groups for testing purpose.CTRI/2020/12/030132Tata Research Administrative Council TRAC
招募中
3 期
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734*) in Participants with Moderate COVID-19 Compared to Standard of Care TreatmentCOVID-19Corona10047438NL-OMON49717Gilead Sciences40
进行中（未招募）
1 期
This study will test a drug named remdesivir (GS-5734™) to evaluate the safety and effectiveness of the drug in treating patients with moderate coronavirus disease 2019 (COVID-19) compared to standard of care treatment.Coronavirus disease 2019 (COVID-19)MedDRA version: 20.0Level: LLTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 100000004862EUCTR2020-000842-32-ITGilead Sciences, Inc.600